TGen, Horizon Discovery Set PGx Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Translational Genomics Research Institute’s TGen Drug Development (TD2) arm will use Horizon Discovery’s isogenic cell lines in a partnership focused on developing pharmacogenomic tools for use in cancer drug research services, TGen said today.

The partners will use Horizon Discovery Services’ panel of more than 200 genetically-defined X-Man human isogenic cell lines in TD2’s comprehensive pre-clinical service before it conducts certain in-house clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.